198 related articles for article (PubMed ID: 30097905)
1. A Network Pharmacology-Based Analysis of Multi-Target, Multi-Pathway, Multi-Compound Treatment for Ovarian Serous Cystadenocarcinoma.
Xiong DD; Qin Y; Xu WQ; He RQ; Wu HY; Wei DM; Zeng JJ; Dang YW; Chen G
Clin Drug Investig; 2018 Oct; 38(10):909-925. PubMed ID: 30097905
[TBL] [Abstract][Full Text] [Related]
2. Molecular Mechanism of Gleditsiae Spina for the Treatment of High-Grade Serous Ovarian Cancer Based on Network Pharmacology and Pharmacological Experiments.
Zhang B; Dan W; Zhang G; Wang X
Biomed Res Int; 2022; 2022():5988310. PubMed ID: 35299895
[TBL] [Abstract][Full Text] [Related]
3. Inferences of carboplatin response-related signature by integrating multiomics data in ovarian serous cystadenocarcinoma.
Yan JQ; Liu M; Ma YL; Le KD; Dong B; Li GH
Exp Biol Med (Maywood); 2022 Jun; 247(11):910-920. PubMed ID: 35285286
[TBL] [Abstract][Full Text] [Related]
4. Network pharmacology-based strategy to investigate pharmacological mechanisms of Tinospora sinensis for treatment of Alzheimer's disease.
Zhou F; He K; Guan Y; Yang X; Chen Y; Sun M; Qiu X; Yan F; Huang H; Yao L; Liu B; Huang L
J Ethnopharmacol; 2020 Sep; 259():112940. PubMed ID: 32389853
[TBL] [Abstract][Full Text] [Related]
5. Differential expression of immune related genes in high-grade ovarian serous carcinoma.
Siamakpour-Reihani S; Cobb LP; Jiang C; Zhang D; Previs RA; Owzar K; Nixon AB; Alvarez Secord A
Gynecol Oncol; 2020 Mar; 156(3):662-668. PubMed ID: 31918995
[TBL] [Abstract][Full Text] [Related]
6. Prediction of chemo-response in serous ovarian cancer.
Gonzalez Bosquet J; Newtson AM; Chung RK; Thiel KW; Ginader T; Goodheart MJ; Leslie KK; Smith BJ
Mol Cancer; 2016 Oct; 15(1):66. PubMed ID: 27756408
[TBL] [Abstract][Full Text] [Related]
7. High expression of mesothelin in advanced serous ovarian cancer is associated with poor prognosis.
Yildiz Y; Kabadayi G; Yigit S; Kucukzeybek Y; Alacacioglu A; Varol U; Taskaynatan H; Salman T; Oflazoglu U; Akyol M; Tarhan MO
J BUON; 2019; 24(4):1549-1554. PubMed ID: 31646807
[TBL] [Abstract][Full Text] [Related]
8. Low-Grade Serous Ovarian Cancer: Current Treatment Paradigms and Future Directions.
Grisham RN; Iyer G
Curr Treat Options Oncol; 2018 Sep; 19(11):54. PubMed ID: 30225651
[TBL] [Abstract][Full Text] [Related]
9. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
10. ZNF671 DNA methylation as a molecular predictor for the early recurrence of serous ovarian cancer.
Mase S; Shinjo K; Totani H; Katsushima K; Arakawa A; Takahashi S; Lai HC; Lin RI; Chan MWY; Sugiura-Ogasawara M; Kondo Y
Cancer Sci; 2019 Mar; 110(3):1105-1116. PubMed ID: 30633424
[TBL] [Abstract][Full Text] [Related]
11. Long Non-Coding RNA HAND2-AS1 Acts as a Tumor Suppressor in High-Grade Serous Ovarian Carcinoma.
Gokulnath P; de Cristofaro T; Manipur I; Di Palma T; Soriano AA; Guarracino MR; Zannini M
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32517089
[TBL] [Abstract][Full Text] [Related]
12. Identification of Hub Genes in High-Grade Serous Ovarian Cancer Using Weighted Gene Co-Expression Network Analysis.
Wu M; Sun Y; Wu J; Liu G
Med Sci Monit; 2020 Mar; 26():e922107. PubMed ID: 32180586
[TBL] [Abstract][Full Text] [Related]
13. Up-regulation of GSTT1 in serous ovarian cancer associated with resistance to TAXOL / carboplatin.
Zhang J; Xie S; Zhou L; Tang X; Guan X; Deng M; Zheng H; Wang Y; Lu R; Guo L
J Ovarian Res; 2021 Sep; 14(1):122. PubMed ID: 34535163
[TBL] [Abstract][Full Text] [Related]
14. Network Pharmacology Identifies the Mechanisms of Action of TaohongSiwu Decoction Against Essential Hypertension.
Liu TH; Chen WH; Chen XD; Liang QE; Tao WC; Jin Z; Xiao Y; Chen LG
Med Sci Monit; 2020 Mar; 26():e920682. PubMed ID: 32187175
[TBL] [Abstract][Full Text] [Related]
15. Multi-omics in high-grade serous ovarian cancer: Biomarkers from genome to the immunome.
Clifford C; Vitkin N; Nersesian S; Reid-Schachter G; Francis JA; Koti M
Am J Reprod Immunol; 2018 Aug; 80(2):e12975. PubMed ID: 29781548
[TBL] [Abstract][Full Text] [Related]
16. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.
Karlan BY; Dering J; Walsh C; Orsulic S; Lester J; Anderson LA; Ginther CL; Fejzo M; Slamon D
Gynecol Oncol; 2014 Feb; 132(2):334-42. PubMed ID: 24368280
[TBL] [Abstract][Full Text] [Related]
17. Mining TCGA database for gene expression in ovarian serous cystadenocarcinoma microenvironment.
Xu Y; Xu Y; Wang C; Xia B; Mu Q; Luan S; Fan J
PeerJ; 2021; 9():e11375. PubMed ID: 33987033
[TBL] [Abstract][Full Text] [Related]
18. Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance.
Ricciardelli C; Lokman NA; Pyragius CE; Ween MP; Macpherson AM; Ruszkiewicz A; Hoffmann P; Oehler MK
Oncotarget; 2017 Mar; 8(11):17819-17832. PubMed ID: 28147318
[TBL] [Abstract][Full Text] [Related]
19. Characterization of MicroRNA-200 pathway in ovarian cancer and serous intraepithelial carcinoma of fallopian tube.
Yang J; Zhou Y; Ng SK; Huang KC; Ni X; Choi PW; Hasselblatt K; Muto MG; Welch WR; Berkowitz RS; Ng SW
BMC Cancer; 2017 Jun; 17(1):422. PubMed ID: 28623900
[TBL] [Abstract][Full Text] [Related]
20. Chromosomal Instability and mTORC1 Activation through PTEN Loss Contribute to Proteotoxic Stress in Ovarian Carcinoma.
Chui MH; Doodnauth SA; Erdmann N; Tiedemann RE; Sircoulomb F; Drapkin R; Shaw P; Rottapel R
Cancer Res; 2019 Nov; 79(21):5536-5549. PubMed ID: 31530568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
